Try our mobile app

VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-IT® Study

Published: 2020-05-14 18:50:00 ET
<<<  go to AMRN company page

First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses

Results of prespecified tertiary endpoint analyses consistent across different types of coronary revascularization procedures, including urgent, emergent, and elective interventions

Percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) reduced by 32% and 39%, respectively, in post hoc exploratory analyses

DUBLIN, Ireland and BRIDGEWATER, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data from the REDUCE-IT® study presented by Benjamin E. Peterson, M.D., Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions, showed that administration of 4 g/day of VASCEPA® (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p